MENU
+Compare
KROS
Stock ticker: NASDAQ
AS OF
May 20, 10:38 AM (EDT)
Price
$14.08
Change
-$0.02 (-0.14%)
Capitalization
572.68M

KROS Keros Therapeutics Forecast, Technical & Fundamental Analysis

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs... Show more

KROS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for KROS with price predictions
May 19, 2025

KROS sees its Stochastic Oscillator climbs out of oversold territory

On May 15, 2025, the Stochastic Oscillator for KROS moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 58 instances where the indicator left the oversold zone. In of the 58 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 10-day moving average for KROS crossed bullishly above the 50-day moving average on April 15, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where KROS advanced for three days, in of 288 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 212 cases where KROS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for KROS moved out of overbought territory on May 06, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 similar instances where the indicator moved out of overbought territory. In of the 42 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on May 06, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on KROS as a result. In of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for KROS turned negative on May 06, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KROS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

KROS broke above its upper Bollinger Band on April 14, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.786) is normal, around the industry mean (16.212). P/E Ratio (0.000) is within average values for comparable stocks, (60.468). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.177). Dividend Yield (0.000) settles around the average of (0.023) among similar stocks. P/S Ratio (2.546) is also within normal values, averaging (281.268).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. KROS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KROS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
KROS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

KROS is expected to report earnings to fall 130.39% to -110 cents per share on July 31

Keros Therapeutics KROS Stock Earnings Reports
Q2'25
Est.
$-1.10
Q1'25
Beat
by $4.81
Q4'24
Beat
by $0.22
Q3'24
Missed
by $0.13
Q2'24
Beat
by $0.01
The last earnings report on May 06 showed earnings per share of $3.62, beating the estimate of -119 cents. With 43.74K shares outstanding, the current market capitalization sits at 572.68M.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which focuses on treatments for rare muscle diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1050 Waltham Street
Phone
+1 617 314-6297
Employees
136
Web
https://www.kerostx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY594.850.65
+0.11%
SPDR® S&P 500® ETF
BTC.X105606.180000-839.828100
-0.79%
Bitcoin cryptocurrency
AAPL208.78-2.48
-1.17%
Apple
GME27.89-0.56
-1.97%
GameStop Corp
TSLA342.09-7.89
-2.25%
Tesla

KROS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, KROS has been loosely correlated with INZY. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then INZY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KROS
1D Price
Change %
KROS100%
+0.21%
INZY - KROS
43%
Loosely correlated
+1.01%
DNLI - KROS
39%
Loosely correlated
+0.94%
XNCR - KROS
38%
Loosely correlated
N/A
ALT - KROS
38%
Loosely correlated
-1.43%
OLMA - KROS
38%
Loosely correlated
+1.91%
More